PRICE T ROWE ASSOCIATES INC /MD/ - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$131
-98.0%
11,678
-92.8%
0.00%
-100.0%
Q1 2023$6,580
-18.8%
162,694
-6.7%
0.00%0.0%
Q4 2022$8,108
-99.9%
174,303
-27.6%
0.00%
-50.0%
Q3 2022$12,485,000
+40.2%
240,687
+27.8%
0.00%
+100.0%
Q2 2022$8,903,000
-35.2%
188,343
-2.4%
0.00%0.0%
Q1 2022$13,742,000
-33.0%
193,059
-29.6%
0.00%
-50.0%
Q4 2021$20,513,000
+37.8%
274,317
+4.7%
0.00%
+100.0%
Q3 2021$14,891,000
+33.9%
262,123
+3.7%
0.00%0.0%
Q2 2021$11,125,000
-73.9%
252,782
-70.8%
0.00%
-75.0%
Q1 2021$42,625,000
+5.3%
864,261
-10.1%
0.00%0.0%
Q4 2020$40,477,000
-9.3%
961,445
-1.3%
0.00%
-20.0%
Q3 2020$44,609,000
-30.7%
974,429
-24.0%
0.01%
-37.5%
Q2 2020$64,397,000
-7.6%
1,282,557
-5.3%
0.01%
-27.3%
Q1 2020$69,684,000
-19.2%
1,354,938
-3.0%
0.01%0.0%
Q4 2019$86,266,000
-7.7%
1,396,335
-10.2%
0.01%
-15.4%
Q3 2019$93,440,000
-27.6%
1,555,252
+1.7%
0.01%
-27.8%
Q2 2019$128,978,000
-1.4%
1,528,541
+11.7%
0.02%
-5.3%
Q1 2019$130,770,000
+72.0%
1,369,037
+27.5%
0.02%
+46.2%
Q4 2018$76,030,000
-16.3%
1,073,422
+1.0%
0.01%0.0%
Q3 2018$90,851,000
-8.4%
1,063,084
+24.3%
0.01%
-13.3%
Q2 2018$99,151,000
+284.9%
855,491
+168.7%
0.02%
+275.0%
Q1 2018$25,762,000
+18.0%
318,404
-14.4%
0.00%0.0%
Q4 2017$21,830,000
+355.4%
372,010
+263.1%
0.00%
+300.0%
Q3 2017$4,794,000102,4440.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 858,811$36,156,00010.56%
Fairmount Funds Management LLC 150,433$6,333,0002.26%
ARMISTICE CAPITAL, LLC 1,356,000$57,088,0001.94%
FARALLON CAPITAL MANAGEMENT LLC 1,775,000$74,728,0000.45%
Virtus ETF Advisers LLC 14,321$603,0000.25%
Granahan Investment Management 231,071$9,728,0000.22%
JACOBS LEVY EQUITY MANAGEMENT, INC 248,320$10,454,0000.09%
ACADIAN ASSET MANAGEMENT LLC 467,514$19,684,0000.08%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 126$5,0000.08%
AIGEN INVESTMENT MANAGEMENT, LP 12,854$541,0000.07%
View complete list of ENANTA PHARMACEUTICALS INC shareholders